98%
921
2 minutes
20
Introduction: Chronic rhinosinusitis with nasal polyps has a high post-surgery recurrence, suggesting complex pathology. However, research into underlying mechanisms and contributing factors, such as gut microbiota, is lacking. This study aimed to investigate the causal relationship between nasal polyps and gut microbiota, and to identify and quantify the potential mediating roles of metabolic pathways. We investigated the cause-and-effect relationship between nasal polyps and the gut microbiota and determined the influence of metabolic pathways as possible mediators.
Methods: This study utilized genetic data from genome-wide association studies. The datasets included nasal polyp data from FinnGen (6,841 cases and 308,457 control samples), microbial metabolic pathway data from the Dutch Microbiome Project (7,738 samples), and single-nucleotide polymorphisms of the gut microbiota from MiBioGen (18,340 samples). First, two-sample Mendelian randomization (MR) analyses were conducted on the gut microbiota, nasal polyps, and metabolic pathways. Next, a two-step MR was employed for mediation analysis to investigate whether metabolic pathways serve as mediators between the gut microbiota and nasal polyps and to estimate the proportion of the effect of metabolism-mediated gut microbiota on nasal polyps.
Results: MR analysis revealed that genus Actinomyces and genus Bifidobacterium are associated with an increased risk of nasal polyps through the inhibition of SO4ASSIM-PWY: sulfate reduction I (assimilatory) and PWY-4242: pantothenate and coenzyme A biosynthesis III, respectively. In contrast, family Desulfovibrionaceae is linked to a reduced risk of nasal polyps by promoting GALACTUROCAT-PWY:
Conclusion: This study identified a causal relationship between the gut microbiota and nasal polyps, with metabolic pathways as mediators. Our study provides new perspectives and possibilities for the study and treatment of chronic rhinosinusitis with nasal polyps.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1159/000546793 | DOI Listing |
J Allergy Clin Immunol Pract
September 2025
Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA. Electronic address:
In recent years, several biologics have been introduced into hospitals and clinics as alternatives to surgery and/or topical/oral cortisone therapy in patients with severe refractory chronic rhinosinusitis with polyps (CRSwNP). Advances in understanding the pathophysiology of CRSwNP in relation to the predominant type 2 endotype have also paved the way for understanding possible overlaps with hypereosinophilic syndrome (HES) and eosinophilic granulomatosis with polyangiitis (EGPA). In this article, we present the biologic treatment options currently approved in Germany for the treatment of severe CRSwNP - dupilumab, omalizumab and mepolizumab - together with guidance on practical management including side effects for the indication of CRSwNP.
View Article and Find Full Text PDFInt J Surg Case Rep
September 2025
Department of Otorhinolaryngology, Al Mouwasat University Hospital, Damascus University, Damascus, Syria; Faculty of Medicine, Damascus University, Damascus, Syria.
Introduction: Antrochoanal polyps (ACPs) typically extend posteriorly into the choana and nasopharynx; orbital invasion is exceptionally rare. This report details an atypical ACP with orbital extension in a coagulopathic patient, highlighting diagnostic and surgical complexities.
Case Presentation: A 46-year-old woman with severe Factor V deficiency (0.
J Leukoc Biol
September 2025
School of Pharmacy and Medical Science and Central Facility for Genomics, Griffith University, Parklands Drive, QLD, Australia.
There is limited understanding of the impact of anti-IL5 treatment on nasal polyp tissue biology in chronic rhinosinusitis with nasal polyps (CRSwNP). This study examined nasal polyp tissue cellular proteome and transcriptome responses to anti-IL5 treatment in CRSwNP utilising spatial profiling. GeoMx™ Digital Spatial Profiling (DSP) of 80 proteins and 1,833 mRNA targets in the polyp stroma and the whole transcriptome (18,815 mRNA targets) in polyp epithelia was undertaken on sinonasal biopsies collected from 20 individuals with eosinophilic CRSwNP before and after 16 and 24 weeks of mepolizumab treatment.
View Article and Find Full Text PDFCrit Rev Immunol
September 2025
Otorhinolaryngology Head and Neck Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Galectin-10(Gal-10)/CLC(Charcot-Leyden crystal) has been discovered to be related to ECRSwNP characterized by high eosinophilic infiltration. We aimed to investigate the effects of Gal-10 on ECRSwNP. A total of 36 tissue samples were collected, including 11 ECRSwNP samples, 15 non-ECRSwNP samples, and 10 Control samples.
View Article and Find Full Text PDF